Stay updated on Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy
Sign up to get notified when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.

Latest updates to the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA new revision tag v3.5.4 has been added, replacing v3.5.3. This indicates a minor maintenance update to the page's documentation.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page footer has been updated to reflect a newer ClinicalTrials.gov UI/site revision (v3.5.3 instead of v3.5.2). This represents a site maintenance/version change rather than a change to the study details.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.5.2 replaces v3.5.0.SummaryDifference0.0%

- Check73 days agoChange DetectedAdded the 2026 Neurol Ther publication detailing EMBARK two-year outcomes and updated the revision to v3.5.0; the older online-ahead-of-print citation and its previous revision (v3.4.3) were removed.SummaryDifference0.1%

- Check80 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check94 days agoChange DetectedAdded a 2026 Neurol Ther publication by Audhya et al. on caregiver-reported experiences with Delandistrogene Moxeparvovec in EMBARK and removed the 2025 online-ahead-of-print Neurol Ther article.SummaryDifference0.0%

Stay in the know with updates to Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.